John Mascarenhas

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. Coltoff A, Mascarenhas J. Relevant updates in systemic mastocytosis. Leuk Res. 2019;81:10-18 pubmed publisher
    ..Expanding our understanding of the underlying molecular mechanisms of SM will continue to inform future therapeutic approaches. ..
  2. Naymagon L, Marcellino B, Mascarenhas J. Eosinophilia in acute myeloid leukemia: Overlooked and underexamined. Blood Rev. 2019;: pubmed publisher
    ..This review examines the significance of eosinophilia in the context of AML, with respect to its presentation, pathology, and cytogenetics, and with special attention to appropriate evaluation and treatment. ..
  3. Venugopal S, Mascarenhas J. Chronic Neutrophilic Leukemia: Current and Future Perspectives. Clin Lymphoma Myeloma Leuk. 2019;19:129-134 pubmed publisher
    ..We also discuss the therapeutic implications of the heterogeneous molecular fingerprint of CNL, focusing on emerging targeted therapies, specifically inhibitors of JAK and MAPK signaling pathways. ..
  4. Schwartz L, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev. 2019;33:74-81 pubmed publisher
    ..Future disease management will rely on clinical trial development focused on new mutational drug targets, combination therapies, and signaling pathway dysregulation. ..
  5. Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol. 2013;161:68-75 pubmed publisher
    ..We conclude that panobinostat is a well-tolerated, clinically active treatment for MF patients, regardless of JAK2 V617F status, and most effective when given at low doses over long periods of time. ..
  6. request reprint
    Lee S, Chary M, Petersen B, Mascarenhas J. Paraneoplastic orthostatic hypotension associated with acute myeloid leukemia. Eur Rev Med Pharmacol Sci. 2015;19:2934-7 pubmed
    ..Physicians should be aware of this unusual occurrence of autonomic neuropathy with AML as delay in treatment of the hematologic malignancy can lead to irreversible neurologic deficit and increased morbidity and mortality. ..
  7. Tremblay D, Carreau N, Kremyanskaya M, Mascarenhas J. Systemic Mastocytosis: Clinical Update and Future Directions. Clin Lymphoma Myeloma Leuk. 2015;15:728-38 pubmed publisher
    ..Here we seek to familiarize clinicians with this orphan disease and review current and future treatment approaches. ..
  8. Geevarghese A, Mascarenhas J. Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms. Clin Lymphoma Myeloma Leuk. 2018;18:519-527 pubmed publisher
    ..We reviewed the current diagnostic, prognostic, and molecular understandings, and we assessed the current and future treatment options for CMML. ..
  9. Coltoff A, Houldsworth J, Keyzner A, Renteria A, Mascarenhas J. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion. Ann Hematol. 2018;97:1155-1167 pubmed publisher
    ..The manuscript is bookended by a clinical vignette that highlights the need for further research and refinement of this clinical tool. ..

More Information

Publications22

  1. Mascarenhas J, Virtgaym E, Stal M, Blacklock H, Gerds A, Mesa R, et al. Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study. Ann Hematol. 2018;97:1369-1374 pubmed publisher
  2. Mascarenhas J. Rationale for combination therapy in myelofibrosis. Best Pract Res Clin Haematol. 2014;27:197-208 pubmed publisher
    ..This manuscript will address the proposed goals of combination therapy approach and review the state of the art in combination experimental therapy for MF. ..
  3. Mascarenhas J, Talpaz M, Gupta V, Foltz L, Savona M, Paquette R, et al. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017;102:327-335 pubmed publisher
    ..Non-hematologic adverse events were largely grade 1 or 2; the most common was fatigue. Treatment with INCB039110 resulted in clinically meaningful symptom relief, modest spleen volume reduction, and limited myelosuppression. ..
  4. Mascarenhas J, Sandy L, Lu M, Yoon J, Petersen B, Zhang D, et al. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Leuk Res. 2017;53:13-19 pubmed publisher
    ..The optimal dosing of panobinostat for the treatment of MF remains somewhat ill-defined but appears to be most effective and better tolerated when administered at lower doses over a prolonged duration of therapy. ..
  5. Mascarenhas J. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2016;16 Suppl:S124-9 pubmed publisher
    ..Current JAK2 inhibitor-based combination therapy approaches are supported by preclinical investigation and are currently being tested in multicenter clinical trials. ..
  6. Bhalla S, Tremblay D, Mascarenhas J. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions. Clin Lymphoma Myeloma Leuk. 2016;16:488-494 pubmed publisher
  7. Lee S, Salehi I, Chary M, Schiano T, Mascarenhas J. "Irony" of managing refractory anemia with transfusional support in hemophagocytic lymphohistiocytosis. Transfus Apher Sci. 2016;55:105-8 pubmed publisher
    ..After receiving sixteen units of packed RBCs, liver iron concentration rose to 6.7?mg/g dry weight, which is highly unusual in other diseases requiring transfusional support. ..
  8. Zahr A, Salama M, Carreau N, Tremblay D, Verstovsek S, Mesa R, et al. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016;101:660-71 pubmed publisher
    ..We discuss the rationale of various anti-fibrogenic treatment strategies targeting the clonal hematopoietic stem/progenitor cell, aberrant signaling pathways, fibrogenic cytokines, and the tumor microenvironment. ..
  9. Choi D, Tremblay D, Iancu Rubin C, Mascarenhas J. Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms. Ann Hematol. 2017;96:919-927 pubmed publisher
    ..The current understanding of immune dysfunction in MPNs and analogous MyMs offers a compelling rationale to study PD-1/PD-L1 inhibition in patients as a novel treatment option. ..
  10. Tremblay D, Marcellino B, Mascarenhas J. Pharmacotherapy of Myelofibrosis. Drugs. 2017;77:1549-1563 pubmed publisher
    ..This review highlights the current landscape of MF pharmacotherapy and explores therapeutic advances underway. ..
  11. Keyzner A, Han S, Shapiro S, Moshier E, Schorr E, Petersen B, et al. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis. Biol Blood Marrow Transplant. 2016;22:2180-2186 pubmed publisher
    ..Baseline splenomegaly did not affect transplantation outcomes. Given the particularly poor outcomes seen in the unrelated donor cohort here and elsewhere, a formal exploration of alternative hematopoietic stem cell sources is warranted. ..
  12. Carreau N, Tremblay D, Savona M, Kremyanskaya M, Mascarenhas J. Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. Blood Rev. 2016;30:349-56 pubmed publisher
    ..This manuscript reviews known and potential implications of IO in MF and highlights the need for prospective clinical investigations of ICT with consideration in the setting of JAK2 inhibitor therapy. ..
  13. Mesa R, Miller C, Thyne M, Mangan J, Goldberger S, Fazal S, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167 pubmed publisher